Document ID: chunk:federal_register_of_legislation:F2023L01427:reg:8:p2
Version: federal_register_of_legislation:F2023L01427
Segment Type: reg
Provision Reference: reg 8 (pt 2/3)
Character Range: 6398–9630

type 2 autoimmune polyglandular syndrome;
(b)          ankylosing spondylitis and seronegative spondyloarthropathies;
(c)          dermatomyositis;
(d)          IgG4-related disease;
(e)          inflammatory bowel disease;
(f)           mixed connective tissue disease;
(g)          polymyositis;
(h)          rheumatoid arthritis;
(i)            scleroderma (progressive systemic sclerosis);
(j)            Sjögren's syndrome; or
(k)          systemic lupus erythematosus;
at the time of the clinical onset or clinical worsening of pericarditis;
(17)      having a heart transplant, lung transplant, kidney transplant or haematopoietic cell transplant before the clinical onset or clinical worsening of pericarditis;
(18)      having a myocardial infarction within the 4 weeks before the clinical onset or clinical worsening of pericarditis;
(19)      having a dissection of the ascending aorta at the time of the clinical onset or clinical worsening of pericarditis;
(20)      having a pulmonary infarction at the time of the clinical onset or clinical worsening of pericarditis;
(21)      having pancreatitis at the time of the clinical onset or clinical worsening of pericarditis;
(22)      having a benign or malignant cancer involving the pericardium at the time of the clinical onset or clinical worsening of pericarditis;
(23)      having a malignant neoplasm with a paraneoplastic pericarditis at the time of the clinical onset or clinical worsening of pericarditis;
(24)      having sarcoidosis or amyloidosis at the time of the clinical onset or clinical worsening of pericarditis;
(25)      having acute or chronic renal failure at the time of the clinical onset or clinical worsening of pericarditis;
Note: Pericarditis can occur in patients who are undergoing haemodialysis or peritoneal dialysis. Chronic renal failure is equivalent to a stage 5 chronic kidney disease with a glomerular filtration rate <15 ml/min/1.73 m2.
(26)      having diabetic ketoacidosis at the time of the clinical onset or clinical worsening of pericarditis;
(27)      taking a drug from the specified list at the time of the clinical onset or clinical worsening of pericarditis;
Note: drug from the specified list is defined in the Schedule1- Dictionary.
(28)      taking a drug which is associated in the individual with the development of pericarditis during drug therapy; and either:
(a)          the improvement of pericarditis within one month of discontinuing or tapering drug therapy; or
(b)          the redevelopment of pericarditis on rechallenge with the same drug; and
where taking the drug continued for at least the 7 days before the clinical onset of pericarditis;
(29)      having a COVID-19 vaccine within the 4 weeks before the clinical onset or clinical worsening of pericarditis;
(30)      having smallpox vaccine within the 4 weeks before the clinical onset or clinical worsening of pericarditis;
(31)      having asbestosis or asbestos related pleural plaques before the clinical onset or clinical worsening of pericarditis;
(32)      inhaling respirable asbestos fibres in an enclosed space at the time material containing asbestos was being applied, removed, cut, drilled, dislodged or disturbed:
(a)          for a